What Is Retatrutide?

How is Retatrutide classified and what is its structure?

Retatrutide is a synthetic, lipidated peptide engineered for activity across three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1) and the glucagon receptor. An agonist is a molecule that activates a receptor.

In the scientific literature it is grouped with other incretin-mimetic peptides — for example the GLP-1 agonist semaglutide and the GIP/GLP-1 dual agonist tirzepatide — and is distinguished by the addition of glucagon-receptor activity.

How is Retatrutide’s mechanism studied in research?

Research into incretin biology characterises these receptors as follows:

• GLP-1 receptor — studied for its role in glucose-dependent insulin signalling.
• GIP receptor — an incretin receptor investigated in glucose and lipid metabolism.
• Glucagon receptor — studied in hepatic glucose output and energy metabolism.

Published research on triple agonism investigates how simultaneous activity at these receptors influences metabolic endpoints in study models.

These statements describe the published scientific record; they are not claims about any effect in humans.

What kind of research has been published on Retatrutide?

Retatrutide has been evaluated in peer-reviewed preclinical and clinical research investigating metabolic endpoints — the original pharmacology was published under the research code LY3437943 — and as an investigational compound it remains the subject of ongoing study. The secondary literature is now substantial: a 2025 review in Biomolecules summarised the triple-agonist mechanism and the phase-2 evidence base. Findings are reported in the primary scientific literature listed below.

What compounds is Retatrutide studied alongside?

Retatrutide sits within the incretin-receptor-agonist research field and is routinely analysed alongside semaglutide (a GLP-1 receptor agonist) and tirzepatide (a GIP/GLP-1 dual agonist) — including in a 2026 living systematic review and network meta-analysis that covered all three. These comparisons describe how the compounds are grouped in published research; they do not imply equivalence between compounds or any human-use indication.

How is Retatrutide supplied, tested and handled?

Lazarus Labs supplies Retatrutide as a lyophilised (freeze-dried) reference material, independently tested to 99%+ purity, with a batch Certificate of Analysis (COA) available. Lyophilised peptides are typically stored cold and protected from light, in line with standard laboratory practice for reference materials.